Mebendazole in \textit{giardiasis}: Systematic review and meta-analysis

Pedro Almirall\textsuperscript{1}, Angel A Escobedo\textsuperscript{2}, Eduardo González-Fraile\textsuperscript{3} and Javier Ballesteros\textsuperscript{4}

\textsuperscript{1}Ministry of Public Healthof Cuba, Cuba
\textsuperscript{2}Hospital Pediátrico Borrás-Marfan, Cuba
\textsuperscript{3}Institute of Psychiatric Research, Spain
\textsuperscript{4}University of the Basque Country, Spain

\textbf{Introduction:} At present, 5-nitroimidazole compounds are the pharmacological cornerstone for people with \textit{Giardia} infections. However, treatment failures are increasingly reported. Mebendazole (MBZ), a benzimidazole compound, has received attention in treating patients with giardiasis since beneficial effects have been demonstrated \textit{in vitro} and \textit{in vivo}.

\textbf{Aim:} The aim of this study was to assess in a systematic review and meta-analysis of randomized controlled trials (RCTs) the efficacy of MBZ compared to other antigiardial agents in children.

\textbf{Methods:} RCTs of MBZ for the treatment of \textit{Giardia} infections published in PubMed and EBSCO host were searched. Application of inclusion and exclusion criteria, data extraction, and assessment of methodological quality were independently performed in duplicate. The endpoint was the parasitological response to therapy.

\textbf{Results:} Seven RCTs were found in the systematic review (639 patients) and were included in the meta-analysis. There is not clinical difference in the parasitological cure between MBZ and metronidazole (MTZ). The relative risk (RR) is 0.88 (95\% CI 0.70-1.10), with a moderate heterogeneity (I\textsuperscript{2}=66\%). The prediction interval expected to cover the results of a new trial is wide enough (0.35-2.21) to support both a parasitological relevant difference favoring MBZ and a parasitological relevant difference favoring MTZ.

\textbf{Conclusions:} This study synthesized available evidence on (and documented) the efficacy of MBZ in treating \textit{Giardia} infection in children. There is no difference in efficacy between MBZ and MTZ regarding parasitological cure. Hence, the decision to support any of the competing treatments should be based not in efficacy but, in other characteristics such as tolerance with the treatment or associated costs. Although our results suggest that MBZ may be an effective treatment option for children with \textit{Giardia} infection, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs.

\textbf{Recent Publications:}


\textbf{Biography}

Pedro Almirall has his expertise giardiasis pharmacotherapy and public health. He has been working for years as a Clinical Epidemiologist and has experience in research, evaluation, and teaching, both in Cuban hospitals and education institutions. He has published his research in international scientific journals and currently, he is pursuing his PhD.